Patients with high-risk advanced ovarian cancer obtained a marginal survival benefit with the addition of bevacizumab ...

The FDA granted accelerated approval to the combination of avutometinib and defactinib (Avmapki Fakzynja Co-pack) for the ...

The U.S. Food and Drug Administration has approved Verastem's combination therapy for patients with a rare type of ovarian ...

The U.S. Federal Drug Administration (FDA) has granted Incyclix Bio Fast Track designation for INX-315 to treat ...

For ovarian cysts that cause pain, medications such as acetaminophen, ibuprofen, or another non-steroidal anti-inflammatory ...

In line with previous clinical trial findings, real-world data show that bevacizumab improves outcomes in patients with ...

Ovarian cancer remains the leading cause of death among cancers affecting the female reproductive system, largely because ...

A panelist discusses how antibody-drug conjugates like mirvetuximab should be sequenced in platinum-resistant ovarian cancer, ...

A real-world study based on information from an electronic health records–derived database reveals limited benefits of adding ...

The seventh warning indicator of poor ovary health or ovarian cancer is a visible change in the bowel movement. Studies have ...

The addition of bevacizumab to first-line (1L) chemotherapy offers real-world benefit to patients with epithelial ovarian cancer with high-risk prognostic factors.

University of South Australia (UniSA) researcher Dr Amanda Lumsden and a transdisciplinary team are jointly designing an ...